metabolomics-conference-2017-scientifictracks

9 / 20

alliedacademies
Biochem Mol biol J
ISSN: 2471-8084
Volume 3, Issue 2
Metabolomics Conference 2017
August 29-30, 2017 Prague, Czech Republic
9th International Conference and Exhibition on
Metabolomics and Systems Biology
Notes:
Page 23
High resolution metabolomics to identify
novel biomarkers in corticosteroid resistant
asthmatic children
Youngja H Park1 , Anne M Fitzpatrick2, Carl Angelo Medriano1 and
Dean P Jones2
1Korea University, Korea
2Emory University, USA
C orticosteroid (CS) treatment is the preferred anti-
inflammatory treatment for adults and children with asthma.
However, a subset of patients fails to respond to combined
systemic and inhaled CS treatment despite very high doses and
prolonged treatment. Due to the uncertainty of the molecular
mechanism for CS-resistant asthma, this study is aimed at
discovering diagnostic biomarkers for early identification
of children resistant to CS. High resolution metabolomics
(HRM) was performed on plasma and urine samples from
CS-respondent and CS-non-respondent children to determine
putative biomarkers related to CS resistance. The metabolic
phenotypes of CS-responders and CS-non-responders were
analyzed using bioinformatics including Manhattan plot with
False Discovery Rate (FDR), Hierarchical Cluster Analysis
(HCA), Kyoto Encyclopedia Genes and Genomes (KEGG)
and Mummichog pathway analysis. The Manhattan plot with
false discovery rate determined 1894 metabolites in plasma
and 30 metabolites in urine significantly altered between
CS-responders and CS-non-responders. The important
metabolites annotated were S-adenosylmethionine (439.1395
m/z, [M+ACN+H]+) and S-adenosylmethionine (378.1448 m/z,
[M+Na]+) in plasma as well as ϒ -glutamylcysteine (236.06
m/z, [M+S(34)+H] +) and Cys-Gly, (253.06 m/z, [M-NH3+H]+),
reducedFMN(517.0794 m/z, [M+NaCl] +). Thus, themetabolites
in glutathione metabolism were altered significantly regarding
CS resistance. The identified biomarkers in urine of asthmatic
children would be extremely beneficial not only for early
detection, but also in the development of therapies aimed at
preventing the irreversible airway damage and lung function
decline associated with CS resistance in severe asthma
among children.
Biography
Youngja H Park completed her MS and PhD in Pharmacology and Toxicology
under Dr. James P Kehrer at University of Texas at Austin in 1990. She
previously had worked as an Assistant Professor in the Department of Medicine
and as the Assistant Director of the Clinical Biomarkers Laboratory at Emory
University School of Medicine since 2013. At Emory University, she developed
LC-MS based metabolomics pipelines to identify novel biomarkers and the
pathways associated with diseases. She published number of metabolomics
papers in Science and Journal of Allergy and Clinical Immunology. Currently,
she moved back to College of Pharmacy, Korea University where she has built
metabolomics core facility after years of experience in research, evaluation
and teaching both in hospital and education institutions. Her career goal is to
identify the novel biomarkers and develop the sensors in early diagnoses of
disease.
Youngja H Park et al., Biochem Mol biol J, 3:2
DOI: 10.21767/2471-8084-C1-002